Novo Nordisk A/S (NYSE:NVO) Trading 3.1% Higher - Here's What Happened

Key Points

• Shares rose 3.1% to about $39.77 after Novo settled its lawsuit with Hims & Hers—clearing the way for Wegovy and Ozempic to be sold via Hims’ telehealth platform—and launched a share‑repurchase programme of up to DKK 15bn, both viewed as de‑risking catalysts.
• Analyst sentiment is mixed with a consensus "Hold"; market concerns remain over competition and potential GLP‑1 price pressure (Zacks noted roughly $50bn in market‑cap losses) and some institutional selling has occurred.
• Novo beat quarterly estimates (EPS $1.01 vs. $0.90; revenue $12.43B vs. $11.97B) and declared a $1.2751 per‑share dividend payable April 8 (record March 30), with a market cap around $177.6B and a trailing P/E near 11.5.

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s stock price rose 3.1% during trading on Monday . The stock traded as high as $39.88 and last traded at $39.7730. Approximately 23,690,162 shares were traded during trading, a decline of 11% from the average daily volume of 26,533,146 shares. The stock had previously closed at $38.58.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo ended its lawsuit and will distribute Wegovy and Ozempic via Hims & Hers’ telehealth platform, opening a digital channel to millions of users and removing legal uncertainty that had been a short-term overhang. Reuters: Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: CEO comments and media coverage framed the agreement as a truce that preserves pricing parity on telehealth platforms and removes the risk of adverse court rulings—a de-risking event for revenue and reputation. CNBC: Hims & Hers shares surge after Novo ends legal feud
• Positive Sentiment: Novo launched an ongoing share-repurchase programme (part of up to DKK 15bn over 12 months), which supports the share base and signals management confidence in cash generation. GlobeNewswire: Novo Nordisk A/S - share repurchase programme
• Neutral Sentiment: Analyst consensus remains cautious (consensus "Hold"), and brokers are updating FY2026 estimates—these are watchpoints but not immediate catalysts. AmericanBankingNews: Novo Nordisk Given Consensus "Hold"
• Negative Sentiment: Market concerns persist: Zacks highlights that NVO lost roughly $50B in market cap amid stronger clinical results from competitors (Lilly) and potential GLP‑1 price pressure—factors that could weigh on margins and valuation. Zacks: NVO Stock Sheds Nearly $50B in Market Cap
• Negative Sentiment: Some institutional selling was reported (Cresset reduced its NVO position), a reminder that positioning and flows can amplify short-term moves. DefenseWorld: Novo Nordisk Shares Sold by Cresset

Analyst Ratings Changes

A number of brokerages recently issued reports on NVO. Nordea Equity Research lowered Novo Nordisk A/S to a "hold" rating in a report on Tuesday, February 24th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price objective for the company in a research note on Tuesday, March 3rd. Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Monday, February 9th. HSBC reaffirmed a "hold" rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Finally, BMO Capital Markets restated a "market perform" rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Five investment analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $53.93.

Novo Nordisk A/S Price Performance

The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The stock has a market capitalization of $177.59 billion, a PE ratio of 11.46 and a beta of 0.73. The stock's fifty day moving average is $51.41 and its 200-day moving average is $52.35.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion during the quarter, compared to analysts' expectations of $11.97 billion. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 52.74%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in the company. Revolve Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC raised its stake in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock worth $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock worth $712,000 after buying an additional 1,587 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in Novo Nordisk A/S in the second quarter valued at approximately $194,000. Finally, Savant Capital LLC raised its position in Novo Nordisk A/S by 3.0% in the second quarter. Savant Capital LLC now owns 13,932 shares of the company's stock valued at $962,000 after purchasing an additional 403 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.